NovaBay Pharmaceuticals Inc (AMEX:NBY)
$ 0.7525 -0.0276 (-3.54%) Market Cap: 3.67 Mil Enterprise Value: 5.08 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 41/100

NovaBay Pharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference Transcript

Sep 29, 2022 / 01:00PM GMT
Release Date Price: $135.36 (-8.15%)
Jeff Cohen
Ladenburg Thalmann - Analyst

Good morning. Thank you for joining us. My name is Jeff Cohen. I'm a research analyst of Ladenburg Thalmann. And thank you for attending today. Next up we have NovaBay Pharma, and we've got Mr. Justin Hall, CEO. Thank you for joining us. The floor is yours.

Justin Hall
NovaBay Pharmaceuticals, Inc. - CEO

All right. Thanks, Jeff. Forward-looking statements with an eye because we're an eye here. Wow, that's groundbreaking.

NovaBay Pharmaceuticals is the parent company for three verticals. First one is Avenova in eye care. The second one is DERMAdoctor in skin care. And then, the third is PhaseOne and NeutroPhase for wound care.

So the one thing that really ties all of these products together is the fact that none of them are cosmetic and none of them are Rx. So we are mainly focused on OTC products, but we are a pharmaceutical company that makes scientifically created and clinically proven products. So while all of them are OTC, none of them are cosmetic. None of them have any sense, fragrances, or

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot